- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.06. | Remix Therapeutics to go public in reverse merger with once high-flying Passage Bio | 2 | BioPharma Dive | ||
| 24.06. | Spurned by FDA, Passage Bio finds exit through merger with Remix Therapeutics | 2 | FierceBiotech | ||
| PASSAGE BIO Aktie jetzt für 0€ handeln | |||||
| 24.06. | Passage Bio fusioniert mit Remix Therapeutics im Rahmen eines Aktientauschs | 1 | Investing.com Deutsch | ||
| 24.06. | Passage Bio to merge with Remix Therapeutics in all-stock deal | 2 | Investing.com | ||
| 24.06. | Passage Bio, Remix Therapeutics announce merger agreement | 2 | Seeking Alpha | ||
| 24.06. | Passage BIO, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 24.06. | Passage Bio and Remix Therapeutics Announce Merger Agreement | 521 | GlobeNewswire (Europe) | Combined company to operate as Remix Therapeutics and advance Remix's pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin Remix's... ► Artikel lesen | |
| 26.05. | Passage BIO, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.05. | Passage BIO, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 28.04. | Passage BIO, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.04. | Passage Bio stock rating cut to Hold by TD Cowen on FDA trial news | 1 | Investing.com | ||
| 21.04. | Regulatorischer Rückschlag: Oppenheimer halbiert Kursziel für Passage Bio | 3 | Investing.com Deutsch | ||
| 21.04. | Oppenheimer cuts Passage Bio stock price target on regulatory setback | 1 | Investing.com | ||
| 21.04. | Chardan downgrades Passage Bio stock rating on strategic review | 1 | Investing.com | ||
| 21.04. | Passage Bio: Chardan stuft Aktie nach strategischer Überprüfung auf 'Neutral' herab | 1 | Investing.com Deutsch | ||
| 20.04. | Lucid downgrades Passage Bio stock rating on funding concerns | 19 | Investing.com | ||
| 20.04. | Why Is Passage Bio Stock Falling In Pre-market? | 15 | RTTNews | ||
| 20.04. | Passage Bio reports biomarker improvements in FTD trial | 2 | Investing.com | ||
| 20.04. | Passage Bio meldet positive Biomarker-Daten in Studie zu frontotemporaler Demenz | 3 | Investing.com Deutsch | ||
| 20.04. | Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates | 272 | GlobeNewswire (Europe) | PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels FDA feedback from recent... ► Artikel lesen |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 82,20 | -0,42 % | Novo Nordisk sucht Volumen, BioNTech sucht Beweise | Pharmaaktien werden derzeit nicht einheitlich bewertet. Der Markt unterscheidet härter zwischen bereits kommerzialisierten Blockbustern, deren Preise unter Druck geraten, und Biotech-Pipelines, die... ► Artikel lesen | |
| AMGEN | 320,00 | +0,79 % | Amgen - AMGN: Pharma-Aktie mit Cup & Handle! | Fliegt der Deckel bald weg? Kursziel Allzeithoch! Amgen (AMGN) erhöht Dividenden seit 2011! Dividendenrendite 2025: 2.91 Prozent! Amgen (AMGN) - US0311621009 Rückblick: Bei dem schwachen US-Gesamtmarkt... ► Artikel lesen | |
| NOVAVAX | 8,240 | -0,84 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| BIOGEN | 182,56 | -1,07 % | Biogen Inc.: Biogen to Highlight Breadth of Alzheimer's Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen | Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer's disease, including clinical, biomarker and safety results for Biogen's investigational tau-targeting ASO, following topline... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 10,590 | +2,52 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| OCUGEN | 1,302 | -0,31 % | Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,000 | +0,15 % | Is Viking Therapeutics Stock Going to $100? | ||
| INTELLIA THERAPEUTICS | 14,880 | -1,85 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema | Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published... ► Artikel lesen | |
| TEMPUS AI | 53,50 | -1,29 % | Biovica International: Biovica Refocuses US Commercial Strategy and Terminates Agreement with Tempus AI | UPPSALA, SE / ACCESS Newswire / June 30, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, specializing in blood-based cancer monitoring, today announces that it has, by... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,506 | +0,35 % | BioCryst Pharmaceuticals, Inc.: BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility | -Advances strategic shift toward a disciplined research model prioritizing external innovation to accelerate rare disease pipeline growth- -Completes enrollment in Phase 3 ALPHA-ORBIT for navenibart... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 50,52 | +1,49 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO (vosoritide) in Children with Hypochondroplasia | Study met primary endpoint, exceeding expectations with a highly statistically significant improvement in annualized growth velocity (AGV, change from baseline)... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,353 | +3,52 % | NurExone-Tochter Exo-Top ebnet Weg in den mexikanischen Exosomenmarkt | ||
| EXELIXIS | 47,675 | +0,54 % | Truist assumes Exelixis stock coverage with Hold rating on pipeline uncertainty | ||
| SAREPTA THERAPEUTICS | 15,880 | -0,87 % | Regulatory tracker: FDA sets decision date for Sarepta's DMD drugs | ||
| CARDIOL THERAPEUTICS | 0,930 | 0,00 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders | TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing... ► Artikel lesen |
Das Unternehmen PASSAGE BIO INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 4,580 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PASSAGE BIO INC finden Sie auf Wallstreet Online.